SCHEMBL1635240

SCHEMBL1635240

CC1CC(C)CC2(C1)CC2C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.35
APLNR P35414 1/20 0.34
GRM6 O15303 3/20 0.33
GRM2 Q14416 2/20 0.33
GRM3 Q14832 2/20 0.33
LMNA P02545 1/20 0.33
PPP1CA P62136 1/20 0.33
GRM4 Q14833 4/20 0.32
CYP2C19 P33261 3/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP1A2 P05177 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
GRM8 O00222 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALOX15 P16050 1/20 0.32
PPP5C P53041 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633445 0.80 EPHX1 (0.32) ALDH1A1KMT2A
SCHEMBL6266090 0.78 CYP1A2 (0.39) APLNRGRM6GRM2GRM3LMNA
SCHEMBL6353216 0.77 GRM2 (0.30) SLC6A4GRM2GRM3CYP1A2ALOX15
SCHEMBL1635228 0.72 CYP3A4 (0.37) LMNACYP2C19ALDH1A1MEN1KMT2A
SCHEMBL20985252 0.72
SCHEMBL301224 0.72
SCHEMBL20985243 0.72
SCHEMBL22519005 0.71 CHRNB2 (0.36) SLC6A4APLNRGRM6GRM4CYP2C19
SCHEMBL6359724 0.71 SLC6A4 (0.35) SLC6A4APLNRGRM6GRM2GRM3
SCHEMBL1634027 0.69 ALDH1A1 (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US claimed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP claimed
EP-1558230-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2005-08-03 EP claimed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US claimed
WO-2004037240-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2004-05-06 WO claimed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US claimed
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US disclosed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP disclosed
EP-1558230-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2005-08-03 EP disclosed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US disclosed
WO-2004037240-A1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2004-05-06 WO disclosed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A SLC6A4 1435/4885APLNR 2206/4885GRM6 137/4885
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A SLC6A4 1435/4885APLNR 2206/4885GRM6 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.